NPJ Precision Oncology最新文献_第3页

Integrative whole slide image and spatial transcriptomics analysis with QuST and QuPath.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-12 DOI: 10.1038/s41698-025-00841-9

Chao-Hui Huang, Sara Lichtarge, Diane Fernandez

引用次数: 0

Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-11 DOI: 10.1038/s41698-025-00857-1

Si-Yu Jing, He-Qi Wang, Ping Lin, Jiao Yuan, Zhi-Xuan Tang, Hong Li

引用次数: 0

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-11 DOI: 10.1038/s41698-025-00838-4

Gary Middleton, Helen L Robbins, Peter Fletcher, Joshua Savage, Manita Mehmi, Yvonne Summers, Alastair Greystoke, Nicola Steele, Sanjay Popat, Pooja Jain, James Spicer, Judith Cave, Paul Shaw, David Gilligan, Danielle Power, Dean Fennell, Maya Bajracharya, David J McBride, Uma Maheswari, Alexander M Frankell, Charles Swanton, Andrew D Beggs, Lucinda Billingham

{"title":"A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.","authors":"Gary Middleton, Helen L Robbins, Peter Fletcher, Joshua Savage, Manita Mehmi, Yvonne Summers, Alastair Greystoke, Nicola Steele, Sanjay Popat, Pooja Jain, James Spicer, Judith Cave, Paul Shaw, David Gilligan, Danielle Power, Dean Fennell, Maya Bajracharya, David J McBride, Uma Maheswari, Alexander M Frankell, Charles Swanton, Andrew D Beggs, Lucinda Billingham","doi":"10.1038/s41698-025-00838-4","DOIUrl":"10.1038/s41698-025-00838-4","url":null,"abstract":"There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with mTORC1/2 inhibition. In arm B2 of the National Lung Matrix Trial 54 patients with NSCLC received vistusertib, of which 49 were STK11-deficient (30 with KRAS mutation (B2D), 19 without (B2S)). Objective response (OR) and durable clinical benefit (DCB) rates with 95% credible intervals (CrI) were estimated from posterior probability distributions generated using Bayesian beta-binomial conjugate analysis. In B2D, 2 per-protocol patients obtained OR (estimated true OR rate (95%CrI) 9.8% (2.4-24.3). Estimates of true DCB rate (95%CrI): B2D 24.4% (11.1-42.3), B2S 14.6% (3.6-34.7). Overall, vistusertib cannot be recommended in this context. Longitudinal ctDNA analysis demonstrates enrichment of SMARCA4 mutations post-treatment. In vitro studies show adaptive resistance to mTORC1/2 inhibition via AKT reactivation. (NCT02664935, ISRCTN38344105, EudraCT 2014-000814-73, 10 June 2015).","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"9 1","pages":"67"},"PeriodicalIF":6.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-10 DOI: 10.1038/s41698-025-00858-0

Pieter-Jan Volders, Philippe Aftimos, Franceska Dedeurwaerdere, Geert Martens, Jean-Luc Canon, Gabriela Beniuga, Guy Froyen, Jacques Van Huysse, Rebecca De Pauw, Hans Prenen, Suzan Lambin, Lore Decoster, Freya Vaeyens, Sylvie Rottey, Pieter-Jan Van Dam, Lynn Decoster, Annemie Rutten, Max Schreuer, Siebe Loontiens, Joni Van der Meulen, Jeroen Mebis, Kristof Cuppens, Sabine Tejpar, Isabelle Vanden Bempt, Jacques De Grève, David Schröder, Cédric van Marcke, Marc Van Den Bulcke, Evandro de Azambuja, Kevin Punie, Brigitte Maes

{"title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.","authors":"Pieter-Jan Volders, Philippe Aftimos, Franceska Dedeurwaerdere, Geert Martens, Jean-Luc Canon, Gabriela Beniuga, Guy Froyen, Jacques Van Huysse, Rebecca De Pauw, Hans Prenen, Suzan Lambin, Lore Decoster, Freya Vaeyens, Sylvie Rottey, Pieter-Jan Van Dam, Lynn Decoster, Annemie Rutten, Max Schreuer, Siebe Loontiens, Joni Van der Meulen, Jeroen Mebis, Kristof Cuppens, Sabine Tejpar, Isabelle Vanden Bempt, Jacques De Grève, David Schröder, Cédric van Marcke, Marc Van Den Bulcke, Evandro de Azambuja, Kevin Punie, Brigitte Maes","doi":"10.1038/s41698-025-00858-0","DOIUrl":"10.1038/s41698-025-00858-0","url":null,"abstract":"The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center study enrolled 872 patients from 12 Belgian hospitals. CGP was performed on tumor tissues using a standardized CGP panel (523 genes) across nine laboratories with success in 93% of patients and a median turnaround time of 29 days. Actionable genomic markers were identified in 81% of patients, substantially higher than the 21% using nationally reimbursed, small panels. A national molecular tumor board (nMTB) recommended treatments for 69% of patients, with 23% receiving matched therapies. Reasons for non-compliance were highly variable across clinical sites. Overall, BALLETT demonstrates the feasibility of implementing decentralized CGP and its potential to identify actionable targets in most patients with advanced cancers. BALLETT reinforces CGP's utility and emphasizes the importance of collaboration, standardization, and addressing implementation challenges.","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"9 1","pages":"66"},"PeriodicalIF":6.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-08 DOI: 10.1038/s41698-025-00840-w

Hong-Lei Qin, Yang Han, Jian-Qi Li, Qing-Hua Wu, Yu-Ping Du, Qian-Hui Li, Xi Chen, Yong-Peng Wang, Xue Guan, Xiu-Jie Sheng, Shuo Chen, Yang Zhao

{"title":"piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer.","authors":"Hong-Lei Qin, Yang Han, Jian-Qi Li, Qing-Hua Wu, Yu-Ping Du, Qian-Hui Li, Xi Chen, Yong-Peng Wang, Xue Guan, Xiu-Jie Sheng, Shuo Chen, Yang Zhao","doi":"10.1038/s41698-025-00840-w","DOIUrl":"10.1038/s41698-025-00840-w","url":null,"abstract":"Conventional targeted therapies primarily rely on small molecules and proteins. However, they often struggle to enter specific protein conformations, which limits their therapeutic effectiveness. In contrast, RNA therapy is emerging as a more precise and effective targeting strategy. Through differential analysis comparing Pandora-Seq data with clinical samples, we discovered that the small RNA piR-28846 naturally, occurring in human body, exhibited low expression levels in ovarian cancer tissues. Experimental results indicate that piR-28846 inhibits the growth of ovarian cancer cells. Additionally, piR-28846 demonstrated significant therapeutic effects in xenograft models and ovarian cancer-like organoids. Further studies revealed that piR-28846 binds to NSUN2 and down-regulates it, which in turn affects the stability of KPNA2 mRNA. Notably, KPNA2 negatively regulates NSUN2 expression and localization. Given its inhibitory effects observed in vivo, in vitro, and in the ovarian cancer organoid model, we believe piR-28846 has strong potential as a small nucleic acid therapy of ovarian cancer.","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"9 1","pages":"65"},"PeriodicalIF":6.8,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of GPX3+ astrocytes in breast cancer brain metastasis activated by circulating tumor cell exosomes.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-07 DOI: 10.1038/s41698-025-00833-9

Guanghui Huang, Gongwen Xu, Qianqian Cao, Sheng Li, Hao Li, Xiaonan Zhang, Xiaomei Li

引用次数: 0

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-07 DOI: 10.1038/s41698-025-00845-5

Jailan Elayoubi, Yu Zong, Erich J Schwartz

引用次数: 0

Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-06 DOI: 10.1038/s41698-025-00846-4

Vinita Akula, Lily Chen, Yusuf Acikgoz, Katherine Klein, Betul Gok Yavuz, Lokman Cevik, Tarik Demir, Ashish Manne, Ilyas Sahin, Ahmed Kaseb, Elshad Hasanov

引用次数: 0

Extended spectrum of cancers in PTEN hamartoma tumor syndrome.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-06 DOI: 10.1038/s41698-025-00847-3

Lamis Yehia, Gilman Plitt, Ann M Tushar, Darren Liu, Julia Joo, Ying Ni, Sujata Patil, Charis Eng

引用次数: 0

LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker.

IF 6.8 1区医学

NPJ Precision Oncology Pub Date : 2025-03-06 DOI: 10.1038/s41698-025-00849-1

Pamela R de Santiago, Sho Sato, Stephanie J Zhang, Meaghan C Dougher, Kyle M Devins, Agnes J Bilecz, Sagar Rayamajhi, Gabriel Mingo, Hannah S Rendulich, Yi Feng, Connie Wu, Martin S Taylor, Yelena Zhuravlev, Euihye Jung, Dalia K Omran, Tian-Li Wang, Ie-Ming Shih, Lauren E Schwartz, Sarah Kim, Mark A Morgan, Janos L Tanyi, Kathleen H Burns, Ernst Lengyel, Carlos Parra-Herran, Andrew K Godwin, David R Walt, Ronny Drapkin

{"title":"LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker.","authors":"Pamela R de Santiago, Sho Sato, Stephanie J Zhang, Meaghan C Dougher, Kyle M Devins, Agnes J Bilecz, Sagar Rayamajhi, Gabriel Mingo, Hannah S Rendulich, Yi Feng, Connie Wu, Martin S Taylor, Yelena Zhuravlev, Euihye Jung, Dalia K Omran, Tian-Li Wang, Ie-Ming Shih, Lauren E Schwartz, Sarah Kim, Mark A Morgan, Janos L Tanyi, Kathleen H Burns, Ernst Lengyel, Carlos Parra-Herran, Andrew K Godwin, David R Walt, Ronny Drapkin","doi":"10.1038/s41698-025-00849-1","DOIUrl":"10.1038/s41698-025-00849-1","url":null,"abstract":"Long interspersed element 1 (LINE-1) retrotransposons are repetitive sequences that can move within the genome by an autonomous mechanism. To limit their mutagenic potential, benign cells restrict LINE-1 expression through molecular mechanisms such as DNA methylation and histone modification, but these mechanisms are usually impaired in cancer. Clear cell ovarian carcinoma (CCOC) represents 5-10% of ovarian cancers and is thought to arise from endometriosis. Women with advanced CCOC face poor prognoses, highlighting the importance of understanding early disease pathogenesis. In our study, 33 of 40 cases (over 82%) of CCOC tumors express ORF1p, a LINE-1-encoded protein. We found that LINE-1 de-repression is an early event in CCOC, as ORF1p is enhanced during the transition from typical to atypical endometriosis and persists in invasive cancer. Finally, using single-molecule array (Simoa) assays, we detected ORF1p in patient blood, suggesting it as a potential minimally invasive biomarker for this disease.","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"9 1","pages":"62"},"PeriodicalIF":6.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0